注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Poseida Therapeutics Inc是一家臨床階段的生物製藥公司,利用其基因工程平台技術開發細胞和基因療法。該公司的平台包括我們的非病毒piggyBac DNA遞送系統、Cas-CLOVER位點特異性基因編輯系統以及基於納米顆粒和AAV的基因遞送技術。其正在開發的先進候選產品P-PSMA-101用於治療轉移性去勢抵抗性前列腺癌(mCRPC)患者,處於I期試驗。其前兩個全同種異體CAR-T候選產品包括P-BCMA-ALLO1和P-MUC1C-ALLO1,均處於I期試驗階段。P-BCMA-ALLO1是為複發/難治性多發性骨髓瘤患者開發的。P-MUC1C-ALLO1正在被開髮用於治療一系列實體瘤,包括乳腺癌、卵巢癌和其他上皮源性癌症。此外,該公司還有幾個額外的同種異體項目向預期的IND申請推進,包括P-CD19CD20-ALLO1。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Mark J. Gergen | 61 | 2018 | Executive Chairman of the Board |
Cynthia L. Collins | 66 | 2021 | Independent Director |
John P. Schmid | 61 | 2018 | Lead Independent Director |
Luca Gattinoni | - | 2021 | Member of Scientific Advisory Board |
Luke David Corning | 42 | 2020 | Independent Director |
Mark A. Kay | 65 | 2023 | Member of Gene Therapy Scientific Advisory Board |
Marcea Bland Lloyd | 75 | 2019 | Independent Director |
Carl H. June | 69 | 2021 | Chairman of Cell Therapy Scientific Advisory Board |
Jan Joseph Melenhorst | - | 2021 | Member of Scientific Advisory Board |
Christine Brown | - | 2021 | Member of Scientific Advisory Board |
Julian Grunewald | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Kathryn A. Whitehead | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Ian E. Alexander | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Charles M. Baum | 66 | 2022 | Independent Director |
Rafael G. Amado | 60 | 2023 | Director |
George McDonald Church | 70 | 2022 | Chairman of Gene Therapy Scientific Advisory Board |
Mark Tracy | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Kristin Yarema | 53 | 2023 | President, CEO & Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核